UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics
(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.
(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.
BELLINGS Intelligence Score: 10
Why it matters
This is a routine equity investment and strategic partnership announcement by a single biotech company, causing a modest stock price move with limited broader credit-market implications.
Sources
Nasdaq
UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics
(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.